Affinity matured and humanized binding domains targeting ror2
OwnerMichael HUDECEK, Justus WEBER +2inventors
InventorsMichael HUDECEK, Justus WEBER, Rebecca S. GOYDEL, Christoph RADER
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies and derivatives thereof such as bispecific antibodies and chimeric antigen receptors (CARs) with affinity matured and/or humanized targeting domains specific to the ROR2 antigen. The invention encompasses the nucleic acids and vectors encoding said antibodies and derivatives, the cells and pharmaceutical compositions containing them, in particular for their use in cancer therapy.
Claims37
An antibody capable of binding to human ROR2 or a derivative thereof capable of binding to human ROR2, wherein the antibody or derivative thereof comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises a CDR3 sequence having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 23, SEQ ID NO:
- 24 and SEQ ID NO:
- 25, and wherein said CDR3 sequence does not have the amino acid sequence of SEQ ID NO:
- 36.
(canceled)
(canceled)
8-9. (canceled)
11-12. (canceled)
14-15. (canceled)
17-18. (canceled)
20-21. (canceled)
(canceled)
(canceled)
29-32. (canceled)
35-36. (canceled)
43-44. (canceled)
Dependencies are inferred from the claim text.